Tina Wanting Zhang1, Jonatan Snir2, R Gabriel Boldt1, George B Rodrigues1, Alexander V Louie1, Stewart Gaede2, Ronald C McGarry3, James J Urbanic4, Megan E Daly5, David A Palma6. 1. Department of Radiation Oncology, London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. 2. Department of Medical Biophysics, London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. 3. Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky. 4. Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, California. 5. Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California. 6. Department of Radiation Oncology, London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. Electronic address: David.Palma@lhsc.on.ca.
Abstract
PURPOSE: Some recent studies have suggested a relationship between cardiac dose and mortality in non-small cell lung cancer (NSCLC), but others have reported conflicting data. The goal of this study was to conduct a systematic review and meta-analysis to provide an evidence-based estimate of the relationship between cardiac dose and mortality in these patients. METHODS AND MATERIALS: A systematic review of MEDLINE (PubMed) and Embase databases (inception to January 2018) was performed according to PRISMA guidelines. Studies that evaluated cardiac dosimetric factors in patients with NSCLC and included outcomes of cardiac events, cardiac mortality, and/or overall survival were identified. RESULTS: From 5614 patients across 22 studies, a total of 214 cardiac dosimetric parameters (94 unique) were assessed as possible predictors of cardiac toxicity or death. Assessed predictors included general (eg, mean heart dose [MHD]), threshold-based (eg, heart V5), and anatomic-based (eg, atria, ventricles) dosimetric factors. The most commonly analyzed parameters were MHD, heart V5, and V30. Most studies did not make corrections for multiplicity of testing. For overall survival, V5 was found to be significant on multivariable analysis (MVA) in 1 of 11 studies and V30 in 2 of 12 studies; MHD was not significant in any of 8 studies. For cardiac events, V5 was found to be significant on multivariable analysis in 1 of 2 studies, V30 in 1 of 3 studies, and MHD in 2 of 4 studies. A meta-analysis of the data could not be performed because most negative studies did not report effect estimates. CONCLUSIONS: Consistent heart dose-volume parameters associated with overall survival of patients with NSCLC were not identified. Multiplicity of testing is a major issue and likely inflates the overall risk of type I errors in the literature. Future studies should specify predictors a priori, correct for multiplicity of testing, and report effect estimates for nonsignificant variables.
PURPOSE: Some recent studies have suggested a relationship between cardiac dose and mortality in non-small cell lung cancer (NSCLC), but others have reported conflicting data. The goal of this study was to conduct a systematic review and meta-analysis to provide an evidence-based estimate of the relationship between cardiac dose and mortality in these patients. METHODS AND MATERIALS: A systematic review of MEDLINE (PubMed) and Embase databases (inception to January 2018) was performed according to PRISMA guidelines. Studies that evaluated cardiac dosimetric factors in patients with NSCLC and included outcomes of cardiac events, cardiac mortality, and/or overall survival were identified. RESULTS: From 5614 patients across 22 studies, a total of 214 cardiac dosimetric parameters (94 unique) were assessed as possible predictors of cardiac toxicity or death. Assessed predictors included general (eg, mean heart dose [MHD]), threshold-based (eg, heart V5), and anatomic-based (eg, atria, ventricles) dosimetric factors. The most commonly analyzed parameters were MHD, heart V5, and V30. Most studies did not make corrections for multiplicity of testing. For overall survival, V5 was found to be significant on multivariable analysis (MVA) in 1 of 11 studies and V30 in 2 of 12 studies; MHD was not significant in any of 8 studies. For cardiac events, V5 was found to be significant on multivariable analysis in 1 of 2 studies, V30 in 1 of 3 studies, and MHD in 2 of 4 studies. A meta-analysis of the data could not be performed because most negative studies did not report effect estimates. CONCLUSIONS: Consistent heart dose-volume parameters associated with overall survival of patients with NSCLC were not identified. Multiplicity of testing is a major issue and likely inflates the overall risk of type I errors in the literature. Future studies should specify predictors a priori, correct for multiplicity of testing, and report effect estimates for nonsignificant variables.
Authors: Yevgeniy Vinogradskiy; Quentin Diot; Bernard Jones; Richard Castillo; Edward Castillo; Jennifer Kwak; Daniel Bowles; Inga Grills; Nicholas Myziuk; Thomas Guerrero; Craig Stevens; Tracey Schefter; Laurie E Gaspar; Brian Kavanagh; Moyed Miften; Chad Rusthoven Journal: Int J Radiat Oncol Biol Phys Date: 2020-01-23 Impact factor: 7.038
Authors: Eric D Morris; Ahmed I Ghanem; Simeng Zhu; Ming Dong; Milan V Pantelic; Carri K Glide-Hurst Journal: Phys Imaging Radiat Oncol Date: 2021-04-16
Authors: Eric D Morris; Kate Aldridge; Ahmed I Ghanem; Simeng Zhu; Carri K Glide-Hurst Journal: J Appl Clin Med Phys Date: 2020-10-18 Impact factor: 2.243